格隆汇12月5日丨赛托生物(300583.SZ)公布，综合考虑国家政策、市场环境及公司发展战略等因素，为 提高公司募集资金的使用效率，经谨慎研究和论证分析，公司拟将原募投项目投资计划进行调整，投资 总额调整为22,937.66万元，募集资金拟投入额调整为13,029.22万元。并拟变更部分募集资金投入到由全 资子公司山东金维多药业有限公司（简称"金维多"）为实施主体的新项目"生物合成技术研发及产业化 项目"（简称"新募投项目"）。新募投项目为更新改造项目，总投资23,713.12万元，拟投入募集资金 12,436.88万元（含利息273.86万元），其中公司拟以募集资金向金维多增资10,000.00万元，拟以募集资 金向金维多提供借款2,436.88万元，其余资金由金维多自筹。 ...

Group 1 - The company, Saito Bio (300583.SZ), announced adjustments to its fundraising investment plans to improve the efficiency of fund usage, with total investment adjusted to 229.3766 million yuan and the amount of raised funds adjusted to 130.2922 million yuan [1] - Part of the raised funds will be redirected to a new project, "Biological Synthesis Technology R&D and Industrialization Project," led by its wholly-owned subsidiary, Shandong Jinweiduo Pharmaceutical Co., Ltd. (referred to as "Jinweiduo") [1] - The new project involves an overall investment of 237.1312 million yuan, with 124.3688 million yuan of raised funds planned for investment, including interest of 2.7386 million yuan [1] Group 2 - The company plans to increase its investment in Jinweiduo by 100 million yuan using the raised funds and provide a loan of 24.3688 million yuan to Jinweiduo, with the remaining funds to be self-raised by Jinweiduo [1]